Assessing molecular changes in blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research focuses on analyzing molecular alterations in patients with precursor hematological cancers, such as MGUS, smoldering myeloma, and early MDS. By utilizing previously collected tissue samples and obtaining minimal additional samples, the study aims to link these molecular changes with clinical outcomes. The goal is to enhance understanding of how these alterations influence the progression of blood cancers and to potentially identify new therapeutic targets. Participants will not undergo any additional clinical procedures beyond standard care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with Known or Suspected Precursor Hematological Cancer
* Including the following subgroups of diseases:

  * Early MDS, including pathologically-confirmed MDS (IPSS Low/Int-1; IPSS-R Very Low/Low) and idiopathic cytopenias of undetermined significance (ICUS);
  * Asymptomatic Multiple Myeloma and Waldenstrom Macroglobulinemia such as monoclonal gammopathy of undermined significance (MGUS) or Smoldering Multiple Myeloma (SMM or SWM);
  * Monoclonal B cell lymphocytosis (MBL);
  * Early stage asymptomatic low-grade lymphomas; or
  * Other precursor conditions or clonal genetic abnormalities of the blood/bone marrow that do not meet criteria for symptomatic hematological malignancy, or patients exposed to prior chemotherapies (e. g., alkylating agents, platinum derivatives, taxanes, topo-2 inhibitors, anti-metabolites, systemic radioisotopes).
* Patients must be at least 18 years of age to participate in this research.
* Inclusion of Women and Minorities -- In accordance with NIH guidelines, women and members of minority groups and their subpopulations will be included in this protocol.

Exclusion Criteria:

* Patients with Known or Suspected Precursor Hematological Cancer are NOT EXCLUDED
* Evidence of symptomatic or active hematological malignancy. Patients enrolled on clinical trials for precursor diseases are NOT excluded from this study.

Where it's running

• Dana-Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting
• Dana Farber Cancer Institute at St. Elizabeth's
  Brighton, Massachusetts, United States Recruiting
• Dana Farber Cancer Institute at Merrimack Valley
  Methuen, Massachusetts, United States Recruiting
• Dana Farber Cancer Institute at Milford Regional Medical Center
  Milford, Massachusetts, United States Recruiting
• Dana Farber Cancer Institute at South Shore
  Weymouth, Massachusetts, United States Recruiting
• West Michigan Cancer Center
  Kalamazoo, Michigan, United States Recruiting

Study contacts

• Principal investigator: Irene Ghobrial, MD — Dana-Farber Cancer Institute
• Study coordinator: Irene Ghobrial, MD
• Email: precursor@partners.org
• Phone: 617-632-4198

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cohort of patients with plasma cell disorders at Peking University First Hospital

  This study is looking at hospitalized patients with plasma cell disorders to see how their treatment and disease status affect their outcomes over time.

  Recruiting Peking University First Hospital · Beijing · NCT05283993

• Lower Dose Cyclophosphamide After Haploidentical Stem Cell Transplant

  This trial tests whether giving half the usual amount of cyclophosphamide after haploidentical stem cell transplantation can still prevent GVHD in adults with blood cancers.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 1 other locations · NCT07719946

• Chlorophyllin to reduce mouth sores before allogeneic stem cell transplant

  This phase II study tests whether taking chlorophyllin by mouth can lower the chances and severity of mouth ulcers in patients aged 12–65 undergoing radiation-based conditioning before a first allogeneic stem cell transplant.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra · NCT07709195

• Age-stratified conditioning regimens to improve outcomes in haploidentical stem cell transplant for myelodysplastic syndrome

  This study tests two conditioning regimens in adults with MDS undergoing haploidentical stem cell transplant to see how age affects outcomes over one year.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07677306

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• Brain network changes in adults with anemia measured by fNIRS

  This project will use functional near-infrared spectroscopy (fNIRS) to see if brain network connections are altered in adults aged 18–65 who have anemia.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07578675

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.